GCRIS

Now showing 1 - 3 of 3

Citation - WoS: 10
Citation - Scopus: 12
The Topography and Sources of Multidimensional Poverty in Turkey
(Springer, 2021-01-03) Karahasan, Burhan Can; Bilgel, Fırat
Economic inequality and poverty have been extensively analyzed in monetary terms. However, other aspects of poverty, such as education, health, environment and standards of living are important factors, essential for human well-being and capabilities. Using a host of non-monetary aspects of poverty, this paper sheds light on the geographical distribution of multidimensional poverty in Turkey. Results from survey data highlight that the regional distribution non-monetary dimensions of poverty is conspicuously different than that of relative monetary poverty in Turkey. Unlike the relative monetary poverty rate, multidimensional poverty measurement reflects the regional underdevelopment problem of Turkey. On the contrary, once monetary poverty is considered in absolute terms, multidimensional and absolute monetary poverty have a similar geographical pattern. Moreover, the decomposition analyses point out that females, old disabled and socially excluded individuals suffer the most from multidimensional poverty. Our combined results show that the isolated eastern regions realize the highest poverty and deprivation at each decomposition level.
Citation - WoS: 15
Citation - Scopus: 15
Economic Outcomes in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate Plus Prednisone
(Springer, 2020-02-28) Lechpammer, Stanislav; Ramaswamy, Krishnan; Wang, Li; Mardekian, Jack; George, Daniel J.; Sandin, Rickard; Schultz, Neil M.; Başer, Onur; Huang, Ahong
Introduction: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naı¨ve metastatic castration-resistant PC (mCRPC) treated with enzalutamide or abiraterone acetate plus prednisone (abiraterone). Methods: We performed a retrospective analysis on 3174 men (18 years or older) utilizing the Veterans Health Administration (VHA) database from 1 April 2014 to 31 March 2018. Men with mCRPC were included if they had at least one pharmacy claim for enzalutamide or abiraterone (ﬁrst claim date = index date) following surgical or medical castration, had no chemotherapy treatment within 12 months prior to the index date, and had continuous VHA enrollment for at least 12 months pre- and post-index date. Men were followed until death, disenrollment, or end of study and were 1:1 propensity score matched (PSM). All-cause and PC-related resource use and costs per patient per month (PPPM) in the 12 months post index were compared between matched cohorts. Results: We identiﬁed 1229 men with mCRPC prescribed enzalutamide and 1945 prescribed abiraterone with mean ages of 74 and 73 years, respectively. After PSM, each cohort had 1160 patients. The enzalutamide cohort had fewer all-cause (2.51 vs 2.86; p\0.0001) and PC-related outpatient visits (0.86 vs 1.03; p\0.0001), with corresponding lower all-cause ($2588 vs $3115; p\0.0001) and PC-related ($1356 vs $1775; p\0.0001) PPPM outpatient costs compared with the abiraterone cohort. Allcause total costs (medical and pharmacy) PPPM ($8085 vs $9092; p = 0.0002) and PC-related total costs PPPM ($6321 vs $7280; p\0.0001) were signiﬁcantly lower in the enzalutamide cohort compared with the abiraterone cohort. Conclusions: Enzalutamide-treated men with chemotherapy-naı ¨ve mCRPC had signiﬁcantly lower resource utilization and healthcare costs compared with abiraterone-treated men. Plain Language Summary: Plain language summary available for this article.
Citation - WoS: 6
Citation - Scopus: 6
Health Outcomes Among Patients Diagnosed With Schizophrenia in the Us Veterans Health Administration Population Who Transitioned From Once-Monthly To Once-Every Paliperidone Palmitate: an Observational Retrospective Analysis
(Springer, 2019-08-08) Khouyr, Antoine El; Wang, Li; Joshi, Kruti; Patel, Charmi; Başer, Onur; Huang, Ahong; El Khoury, Antoine
There is limited literature on treatment patterns, healthcare resource utilization (HRU), and costs among patients who transition from once-monthly paliperidone palmitate (PP1M) to once-every-3-month paliperidone palmitate (PP3M) in a real-world setting. Hence, this study compared treatment patterns, HRU, and costs 12-month pre- and post-PP3M transition among Veteran’s Health Administration (VHA) patients with schizophrenia.

Ekonomi Bölümü Koleksiyonu

Browse

Filters

Settings

Sort By

Results per page

Search Results